Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ezetimibe
Drug ID BADD_D00864
Description Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating the effect of ezetimibe on intestinal cholesterol absorption.[A15202] Ezetimibe is used as an adjunctive therapy to a healthy diet to lower cholesterol levels in primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia (phytosterolemia).[L11347] Unlike other classes of cholesterol-reducing compounds including statins and bile acid sequestrants, ezetimibe has a distinct mechanism of action involving the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1), and is unique in that it does not affect the absorption of fat-soluble nutrients such as fat-soluble vitamins, triglycerides, or bile acids.[A33313] In genetically NPC1L1-deficient mice, a 70% reduction in intestinal cholesterol absorption was seen, and these mice were insensitive to ezetimibe treatment - it was determined based on these findings that NPC1L1 plays an essential role in promoting intestinal cholesterol uptake via an ezetimibe-sensitive pathway.[A15202] By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces the delivery of intestinal cholesterol to the liver.[L11347]
Indications and Usage For use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
Marketing Status Prescription
ATC Code C10AX09
DrugBank ID DB00973
KEGG ID D01966
MeSH ID D000069438
PubChem ID 150311
TTD Drug ID D09LWS
NDC Product Code 60429-982; 72189-118; 63629-7413; 66039-839; 0591-3713; 70966-0027; 70518-2262; 0781-5690; 65096-0113; 69218-0400; 55111-079; 71205-277; 51660-200; 50228-379; 66039-896; 78206-178; 65015-812; 50268-298; 68382-773; 59651-052; 71335-1354; 50090-3657; 71335-0933; 71205-145; 16729-433; 75895-0281; 70518-3334; 58032-2004; 71335-1127; 50090-3087; 69218-0800; 15894-0011; 70771-1109; 66039-869; 68554-0085; 16714-813; 59651-056; 60687-373; 0615-8300; 0904-6664; 71335-0684; 64176-0042; 69238-1154; 0904-7103; 60505-2945; 14501-0008; 67877-490
Synonyms Ezetimibe | (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone) | Ezetimib | Ezetrol | SCH 58235 | 58235, SCH | SCH-58235 | SCH58235 | Zetia
Chemical Information
Molecular Formula C24H21F2NO3
CAS Registry Number 163222-33-1
SMILES C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000314%Not Available
Drug hypersensitivity10.01.01.0010.004398%Not Available
Drug interaction08.06.03.001--Not Available
Dry mouth07.06.01.0020.000314%
Dysarthria19.19.03.001; 17.02.08.0010.000471%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.0010.000314%
Dysphagia07.01.06.0030.002042%
Dyspnoea22.02.01.004; 02.01.03.002--
Eczema23.03.04.0060.000314%
Eosinophilia01.02.04.0010.000942%
Erythema23.03.06.0010.000785%Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye swelling06.08.03.0030.000471%Not Available
Eyelid ptosis17.17.02.004; 06.05.01.0020.000314%Not Available
Faeces discoloured07.01.03.0020.000314%Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.001414%Not Available
Feeling hot08.01.09.0090.000471%Not Available
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.0070.000314%
Flatulence07.01.04.0020.000785%
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gait disturbance08.01.02.002; 17.02.05.0160.001100%
Gallbladder disorder09.03.02.001--Not Available
Gamma-glutamyltransferase increased13.03.01.011--
Gastric cancer16.13.03.001; 07.21.02.0010.000314%Not Available
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.0030.000628%
Gastrointestinal disorder07.11.01.0010.000785%Not Available
Gastrointestinal pain07.01.05.0050.000314%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages